Happel David, President and CEO of Sagimet Biosciences Inc. ($SGMT), sold shares on the open market twice in the last 365 days for a total of $663,000. His most recent sale occurred on February 10, 2026. These sales rank 5,873rd among 11,678 individual insiders in our database, where the average sale totals $8.6 million across about 6.4 transactions. Happel David made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | A | Stock Option (Right to Buy) | 256000 | $0.00 | 256,000.0000 | 32,464,893 | 9999.99% | 0.79% |
| Feb. 19, 2026 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | A | Series A Common Stock | 128000 | $0.00 | 805,621.0000 | 32,464,893 | 18.89% | 0.39% |
| Feb. 10, 2026 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | S | Series A Common Stock | 12101 | $5.36 | 677,621.0000 | 32,464,893 | 1.75% | 0.04% |
| July 21, 2025 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | S | Series A Common Stock | 65478 | $9.13 | 689,722.0000 | 32,195,366 | 8.67% | 0.20% |
| Feb. 6, 2025 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | A | Series A Common Stock | 116000 | $0.00 | 755,200.0000 | 31,350,725 | 18.15% | 0.37% |
| Feb. 6, 2025 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | A | Stock Option (Right to Buy) | 472000 | $0.00 | 472,000.0000 | 31,350,725 | 9999.99% | 1.51% |
| March 26, 2024 | Sagimet Biosciences Inc. | $SGMT | Happel David | President & CEO | P | Series A Common Stock | 12100 | $5.27 | 639,200.0000 | 10,460,335 | 1.93% | 0.12% |